Rosenfeld B A, Faraday N, Campbell D, Dise K, Bell W, Goldschmidt P
Department of Anesthesiology and Critical Care Medicine, Johns Hopkins Medical Institutions, Baltimore, Maryland.
Anesthesiology. 1994 Nov;81(5):1116-26. doi: 10.1097/00000542-199411000-00005.
Surgery causes changes in hemostasis, leading to a hypercoagulable state. This postoperative increase in hemostatic function is attenuated in patients receiving regional anesthesia compared with those receiving general anesthesia. Regional anesthesia also decreases the neuroendocrine response to surgery compared with general anesthesia, and this effect is hypothesized to be responsible for the differences in hemostatis. To test the hypothesis that neuroendocrine hormones cause changes in hemostasis, we infused stress hormones into normal volunteers and measured hemostatic function.
After drug screening, 12 normal volunteers were studied. On two admissions, volunteers randomly received either stress hormone (epinephrine, cortisol, or glucagon) or placebo infusion for 24 h. During infusion, patients remained at bed rest and received controlled meals. Blood was obtained from indwelling venous catheters before infusion and 2, 8, and 24 h after the start of infusion. Blood was analyzed for neuroendocrine hormone concentrations, glucose, complete blood count, coagulation proteins, platelet reactivity, and activity of the fibrinolytic system.
In the stress hormone group, concentrations of epinephrine, norepinephrine, cortisol, glucagon, and insulin were increased during the infusion period compared with those in the placebo group. Glucose concentrations and white blood cell counts were increased in the stress hormone group compared with those in the placebo group. Circulating fibrinogen concentrations increased 30% and ex vivo collagen-induced platelet reactivity increased 123% (aggregation) and 103% (dense granule release) in the stress hormone infusion group, whereas there was no change in the placebo group. Fibrinolytic proteins were similar in both groups, demonstrating a decrease in plasminogen activator inhibitor-1 activity at 8 and 24 h (196% in the hormone group vs. 199% in the placebo group).
Infusion of stress hormones to concentrations found during surgery is safely tolerated and causes metabolic changes observed with surgery. Stress hormone infusion increases ex vivo platelet reactivity and fibrinogen concentrations that resemble changes seen postoperatively but does not recreate the postoperative decrease in fibrinolytic activity. Differences in neuroendocrine response between types of anesthesia may explain some postoperative changes in platelet function and acute phase reactivity, but additional uncharacterized factors are responsible for the differences in fibrinolysis.
手术会引起止血功能的改变,导致血液高凝状态。与接受全身麻醉的患者相比,接受区域麻醉的患者术后止血功能的这种增强会减弱。与全身麻醉相比,区域麻醉还会降低手术引起的神经内分泌反应,并且据推测这种效应是导致止血差异的原因。为了验证神经内分泌激素会引起止血功能改变这一假设,我们向正常志愿者体内输注应激激素并测量止血功能。
经过药物筛选后,对12名正常志愿者进行了研究。在两次入院期间,志愿者随机接受应激激素(肾上腺素、皮质醇或胰高血糖素)或安慰剂输注24小时。输注期间,患者卧床休息并接受定量饮食。在输注前以及输注开始后2小时、8小时和24小时,从留置的静脉导管采集血液。对血液进行神经内分泌激素浓度、葡萄糖、全血细胞计数、凝血蛋白、血小板反应性以及纤溶系统活性的分析。
在应激激素组中,与安慰剂组相比,输注期间肾上腺素、去甲肾上腺素、皮质醇、胰高血糖素和胰岛素的浓度升高。与安慰剂组相比,应激激素组的葡萄糖浓度和白细胞计数升高。在应激激素输注组中,循环纤维蛋白原浓度增加了30%,体外胶原诱导的血小板反应性增加了123%(聚集)和103%(致密颗粒释放),而安慰剂组没有变化。两组的纤溶蛋白相似,在8小时和24小时时纤溶酶原激活物抑制剂-1活性均降低(激素组为196%,安慰剂组为199%)。
将应激激素输注至手术期间所发现的浓度是安全可耐受的,并会引起手术时所观察到的代谢变化。应激激素输注会增加体外血小板反应性和纤维蛋白原浓度,这与术后所见变化相似,但不会重现术后纤溶活性的降低。不同类型麻醉之间神经内分泌反应的差异可能解释了血小板功能和急性期反应的一些术后变化,但纤溶差异还存在其他未明确的因素。